RxDoctor Payments Data

Shane Matheny, DO

Cardiovascular Disease · Pickerington, OHNPI 1831301548

Payments from drug & device makers

$447in general payments, 2019–2025

Across 32 payments — averaging $13.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$213
  • Boehringer Ingelheim$63
  • Amgen$48
  • Pfizer$39
  • Medtronic$32
  • E.r. Squibb & Sons, L.L.C.$20
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$43397%
  • Education$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis19$213
Boehringer Ingelheim3$63
Amgen3$48
Pfizer2$39
Medtronic(2 entities)2$32
E.r. Squibb & Sons, L.L.C.1$20
Novo Nordisk1$18
AstraZeneca1$14

How this compares

$447 in reported general payments places this provider in the 25th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$112,559
Medicare patients
1,155
Services billed
1,977

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban653$509,060
EntrestoSacubitril/Valsartan189$170,858
Repatha SureclickEvolocumab112$80,611
XareltoRivaroxaban102$75,441
FarxigaDapagliflozin Propanediol26$21,211
Ranolazine ErRanolazine61$10,385
VascepaIcosapent Ethyl28$8,946
Metoprolol Succinate720$7,424
Ezetimibe316$6,129
Atorvastatin Calcium685$5,027
Prasugrel Hcl18$2,040
Rosuvastatin Calcium176$1,837
Diltiazem 24hr Er (Cd)Diltiazem Hcl70$1,605
Isosorbide Mononitrate ErIsosorbide Mononitrate166$1,191
Spironolactone138$836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$509,060653 claims
NovartisEntresto$213$170,858189 claims
AstraZenecaFarxiga$14$21,21126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Pickerington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →